Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.52 |
| ▸ | AXL | P30530 | 2/20 | 0.52 |
| ▸ | METAP2 | P50579 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260364 | 1.00 | NOS1 (0.52) | NOS1AXLMETAP2IDO1KIT | |
| Hydrochloric Acid SCHEMBL1056437 | 0.98 | NOS1 (0.50) | NOS1AXLMETAP2IDO1KIT | |
| SCHEMBL10593960 | 0.86 | HCAR2 (0.47) | NOS1AXLMETAP2IDO1NPC1 | |
| SCHEMBL3732430 | 0.85 | METAP2 (0.61) | NOS1AXLMETAP2IDO1KIT | |
| SCHEMBL1134888 | 0.84 | CSF1R (0.56) | NOS1AXLMETAP2IDO1KIT | |
| SCHEMBL7379757 | 0.84 | NOS1 (0.50) | NOS1AXLMETAP2IDO1KIT | |
| SCHEMBL29360810 | 0.84 | CSF1R (0.56) | NOS1AXLMETAP2IDO1KIT | |
| SCHEMBL29702928 | 0.82 | NOS1 (0.53) | NOS1AXLMETAP2IDO1KIT | |
| SCHEMBL24112335 | 0.80 | METTL3 (0.55) | KITMETTL3 | |
| SCHEMBL543898 | 0.80 | METTL3 (0.50) | NOS1AXLIDO1KITNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054488-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| EP-4396176-A1 | INDOLE COMPOUNDS AND USES THEREOF IN THE TREATEMENT OF CYSTIC FIBROSIS | GENZYME CORPORATION (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
| WO-2023034946-A1 | INDOLE COMPOUNDS AND USES THEREOF IN THE TREATEMENT OF CYSTIC FIBROSIS | GENZYME CORPORATION (US) | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | NOS1 2002/4885AXL 3726/4885METAP2 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.